Clinical features of 337 patients with recurrent nasopharyngeal carcinoma

Li, Jia Xin; Lu, Tai Xiang; Huang, Ying; Han, Fei; Chen, Chun Yan; Xiao, Weiwei

doi:10.5732/cjc.009.10412

Cited by 33 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As both our primary NPC and recurrent NPC cases are associated with EBV, we expected that plasma EBV miRNAs had similar patterns in the 2 groups. 28 In our previous study of circulating EBV BART7, we also noticed that recurrent NPC had significantly lower circulating BART7-3P in comparison with primary NPC. Of the 40 EBV BART miRNAs, only 6 were consistently detected in the plasma from recurrent NPC patients.…”

Section: Discussionmentioning

confidence: 69%

“…25 In a retrospective study of recurrent NPC patients in Hong Kong, it has been shown that over 50% primary NPC patients will develop recurrent disease within 2 years. 28 Therefore, developing effective mean to detect the recurrent NPC is clinically useful to the NPC patients in order to provide timely treatment. 28 Therefore, developing effective mean to detect the recurrent NPC is clinically useful to the NPC patients in order to provide timely treatment.…”

Section: Discussionmentioning

confidence: 99%

“…26,27 In the study carried out by Sun Yat-sen University, the 2-year cumulative recurrence cases were around 49%. 28 Therefore, developing effective mean to detect the recurrent NPC is clinically useful to the NPC patients in order to provide timely treatment. As both our primary NPC and recurrent NPC cases are associated with EBV, we expected that plasma EBV miRNAs had similar patterns in the 2 groups.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Detection of Epstein–Barr virus (EBV)‐encoded microRNAs in plasma of patients with nasopharyngeal carcinoma

Gao

Wong

et al. 2018

Head & Neck

View full text Add to dashboard Cite

Background Nasopharyngeal carcinoma (NPC) latently infected by Epstein–Barr virus (EBV) expresses 40 EBV BART microRNAs (miRNAs). Difference in diagnostic efficacy of these miRNAs on NPC detection was observed. Here, we performed a comprehensive evaluation on the efficacy of these miRNAs. Methods Quantitative polymerase chain reaction was performed on plasma nucleic acid isolated from patients with NPC and noncancer donors. Results For primary NPC, BART2‐5P, BART6‐3P, BART7‐3P, BART7‐5P, BART9‐5P, BART11‐3P, BART17‐5P, and BART19‐5P were significantly elevated. For recurrent NPC, plasma levels of BART2‐3P, BART2‐5P, BART5‐3P, BART5‐5P, BART6‐3P, BART8‐3P, BART9‐5P, BART17‐5P, BART19‐3P, and BART20‐3P were significantly increased. Area under curve (AUC) analysis showed that BART19‐5P had the best performance to identify NPC which was serologically EBV DNA undetectable. For recurrent NPC, BART8‐3P and BART10‐3P had highest AUC value for identifying cancer in EBV DNA undetectable plasma. Conclusion Our data supported the use of circulating EBV miRNAs in NPC and recurrent NPC detection.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of Epstein–Barr virus (EBV)‐encoded microRNAs in plasma of patients with nasopharyngeal carcinoma

Gao

Wong

et al. 2018

Head & Neck

View full text Add to dashboard Cite

show abstract

“…According to data from the Sun Yat-sen University Cancer Center (Guangzhou, PR China), most patients experience recurrence within 3 years of initial treatment: 5.9% within 6 months, 23.7% within less than 1 year, 48.7% within less than 2 years, 16.9% after 5 years, and 3.3% after 10 years 4 . A study from Hong Kong by Lee et al reported that 52% of patients developed rnpc within 2 years, and 39%, within 2-5 years 8 .…”

Section: Patho-clinical Characteristicsmentioning

confidence: 99%

Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge

et al. 2013

View full text Add to dashboard Cite

Recurrent nasopharyngeal carcinoma, which represents a small proportion of head-and-neck cancers, has a unique set of patho-clinical characteristics. The management of recurrent nasopharyngeal carcinoma remains a challenging clinical problem. Traditional treatments offer limited local control and survival benefits; more seriously, they frequently induce severe late complications. Recently, novel treatment techniques and strategies—including precision radiotherapy, endoscopic surgery or transoral robotic resection, third-generation chemotherapy regimens, and targeted therapies and immunotherapy—have provided new hope for patients with recurrent nasopharyngeal carcinoma. Some of these patients can potentially be cured with modern treatments. However, a lack of adequate evidence makes it difficult for clinicians to apply these powerful techniques and strategies. Individualized management guidelines, full evaluation of quality of life in these patients, and a further understanding of the mechanisms underlying recurrence are future directions for research into recurrent nasopharyngeal carcinoma.

show abstract

“…Al-Rajhi et al [36] observed that the majority of patients had advanced disease (stage III and IV) at the time of evaluation (79.2 %), while Li et al [38] observed diseases at stages I/II accounted for 25.2 %, while those with stage III/IV accounted for 74.8 % [37]. Similarly in our study, majority of patients presented with stage III and IV 68.2 %.…”

Section: Discussionmentioning

confidence: 99%

Nasopharyngeal Carcinoma: A 15 Year Study with Respect to Clinicodemography and Survival Analysis

Wani

Khan

Wani³

et al. 2016

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a rare malignancy in Kashmir with distinct pattern, hence we planned to study its clinicodemographic and survival profile. Kashmir has unique lifestyle and dietary habits which may be the source of carcinogenic compounds, most likely implicated in causation of NPC. A total of 148 patients of NPC registered from January 2000 to December 2014 were analyzed. The Mean ± SD age was 45.15 ± 17.092 years (range 11-85 years). The males were 72.3 % (N = 107) with male: female ratio of 2.61:1. Most of the patients were from rural area 81.90 % (N = 95) and non-smokers were 53.44 % (N = 62). Neck swelling was commonest presentation. WHO Type III NPC was commonest histopathological diagnosis 65.3 % (N = 92). Stage IV 36.1 % (N = 51) was commonest stage followed by stage III was 32 % (N = 46). Majority of the patients of NPC received CCRT 68.7 % (N = 78) followed by SCRT 13 % (N = 15) and Induction ? CCRT 13 % (N = 15). The overall mean survival of NPC was 49.56 months. There was no significant correlation of age, gender, smoking, histopathology and treatment on the overall survival. However the stage was the only strong predictor of overall survival. Also the patients with intracranial extension had low survival which is turn depicts the advanced stage of disease. NPC survival is directly related to the stage of the disease irrespective of the treatment modality received. The negative EBV status in our patients implies that there are other risk factors involved in the causation of NPC for which further studies are needed to establish the etiological insult.

show abstract

Clinical features of 337 patients with recurrent nasopharyngeal carcinoma

Abstract: The most common interval of relapse is about 2 years. The relapsed disease is usually more widespread and located deeper. Most recurrent NPC is advanced disease.

Cited by 33 publications

References 0 publications

Detection of Epstein–Barr virus (EBV)‐encoded microRNAs in plasma of patients with nasopharyngeal carcinoma

Detection of Epstein–Barr virus (EBV)‐encoded microRNAs in plasma of patients with nasopharyngeal carcinoma

Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge

Nasopharyngeal Carcinoma: A 15 Year Study with Respect to Clinicodemography and Survival Analysis

Contact Info

Product

Resources

About